Price movement over the last 24 hours
Agilent Technologies Inc vs State Street SPDR Bloomberg High Yield Bond ETF — how do they compare? Agilent Technologies Inc trades at $128.59 (market cap $37.04B), while State Street SPDR Bloomberg High Yield Bond ETF trades at $95.88. The key difference: Agilent Technologies Inc pays a 0.78% dividend while State Street SPDR Bloomberg High Yield Bond ETF pays none. Which is the better fit depends on your goals.
| A | JNK | |
|---|---|---|
Market Cap | $37.04B | — |
Sector | Health | Fixed Income |
52-Week High | $157.20 | $98.19 |
52-Week Low | $110.24 | $94.66 |
Enterprise Value | $38.59B | — |
Dividend Yield | 0.78% | — |
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $131.14, up 0.34% on the day, with a bearish technical signal but strong analyst support. The stock shows solid profitability with a net margin of 19.55% and ROE of 21.33%, supported by recent earnings beats. Recent acquisitions like Biocare Medical highlight growth initiatives, while cash flow trends remain positive. Valuation ratios such as P/E of 26.22 are elevated but align with quality growth expectations.
The outlook is positive given analyst consensus with a $154.90 price target and 77.5% buy ratings. Risks include execution of acquisitions and macroeconomic pressures on life sciences spending. The stock offers growth potential from AI-driven product launches, though technical resistance near $132 may cap near-term gains.
JNK trades at $96.15 with a slight 0.17% daily gain, but technical indicators show a bearish trend with 15 sell signals versus 1 buy. The ETF maintains consistent dividend distributions, with recent payouts around $0.52-$0.53. Market sentiment is cautious amid Federal Reserve uncertainty and inflation concerns, while bond ETF inflows hit record levels according to CNBC on June 25, 2026.
Outlook remains pressured by rising rate hike expectations and high-yield bond vulnerabilities. Risks include Fed policy shifts and economic volatility, but the ETF's yield appeal persists for income-focused investors. Analyst consensus is bearish, with Seeking Alpha rating JNK a SELL on June 15, 2026, citing exhausted tailwinds.
Trailing returns across standard periods
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →JNK is a major ETF tracking the Bloomberg High Yield Very Liquid Index. It provides exposure to U.S. dollar-denominated junk bonds with above-average liquidity, featuring 2026 top holdings like EchoStar, Cloud Software Group, and Carnival Corp.
Read more on JNK →